57,713 Pfizer Inc. $PFE Shares Purchased by Wedmont Private Capital

Wedmont Private Capital raised its stake in Pfizer Inc. (NYSE:PFE) by 138.1% during the third quarter, HoldingsChannel reports. The institutional investor owned 99,498 shares of the biopharmaceutical company’s stock after acquiring an additional 57,713 shares during the period. Wedmont Private Capital’s holdings in Pfizer were worth $2,768,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in the stock. Werlinich Asset Management LLC increased its position in shares of Pfizer by 0.4% during the third quarter. Werlinich Asset Management LLC now owns 92,600 shares of the biopharmaceutical company’s stock worth $2,641,000 after buying an additional 400 shares during the period. Journey Retirement Planning & Investment Management LLC acquired a new position in Pfizer in the third quarter valued at $222,000. WoodTrust Financial Corp boosted its position in Pfizer by 0.3% during the third quarter. WoodTrust Financial Corp now owns 418,180 shares of the biopharmaceutical company’s stock valued at $11,927,000 after acquiring an additional 1,294 shares during the last quarter. Gerald Baker Financial Group LLC grew its holdings in Pfizer by 7.5% during the 3rd quarter. Gerald Baker Financial Group LLC now owns 28,444 shares of the biopharmaceutical company’s stock worth $811,000 after acquiring an additional 1,983 shares during the period. Finally, O Keefe Stevens Advisory Inc. grew its holdings in Pfizer by 8.1% during the 3rd quarter. O Keefe Stevens Advisory Inc. now owns 87,085 shares of the biopharmaceutical company’s stock worth $2,484,000 after acquiring an additional 6,517 shares during the period. 68.36% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

PFE has been the topic of a number of recent analyst reports. Cantor Fitzgerald boosted their price objective on Pfizer from $27.00 to $28.00 and gave the company a “neutral” rating in a research note on Thursday. BMO Capital Markets decreased their target price on Pfizer from $34.00 to $30.00 and set an “outperform” rating for the company in a research note on Monday, July 13th. Wall Street Zen downgraded Pfizer from a “buy” rating to a “hold” rating in a report on Saturday. Bank of America cut their price target on Pfizer from $27.00 to $26.00 and set a “neutral” rating on the stock in a report on Friday, July 10th. Finally, Scotiabank raised their price objective on shares of Pfizer from $30.00 to $33.00 and gave the stock an “outperform” rating in a research report on Tuesday. Five equities research analysts have rated the stock with a Buy rating, fourteen have given a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, Pfizer presently has a consensus rating of “Hold” and an average target price of $28.72.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Analyst support improved: JPMorgan raised its price target from $28 to $30 while maintaining a neutral rating, and Jefferies issued a buy rating. Cantor Fitzgerald also increased its target to $28, signaling some potential downside protection at current levels.
• Positive Sentiment: TUKYSA approval expands Pfizer’s oncology opportunity: The FDA approved TUKYSA in combination with trastuzumab and pertuzumab as a chemotherapy-free frontline maintenance treatment for certain patients with HER2-positive metastatic breast cancer. Moving the drug into an earlier line of treatment could broaden its commercial reach. FDA Backs Pfizer’s TUKYSA Combination
• Positive Sentiment: Pipeline progress adds longer-term support: Pfizer’s Phase 3 trial of tilrekimig, an asthma candidate, is advancing. Investors are also focused on oncology sales, biosimilars and the late-stage pipeline ahead of quarterly results. Tilrekimig Phase 3 Trial Update
• Positive Sentiment: Income and valuation appeal remain catalysts: Pfizer’s dividend announcement, roughly 6% yield and valuation below many large pharmaceutical peers continue to attract income and value-oriented investors. The company also has a history of earnings beats, with its latest reported quarter exceeding consensus estimates for both earnings and revenue.
• Neutral Sentiment: Investor attention is elevated: Pfizer was among heavily searched stocks, while broader biotechnology interest was helped by Moderna’s Nasdaq-100 inclusion. These factors may increase trading activity but do not directly change Pfizer’s fundamentals.
• Negative Sentiment: High yield raises risk concerns: Commentary warns that Pfizer’s unusually large dividend yield may reflect investor doubts about earnings, cash flow, debt and the durability of the payout. Sluggish revenue growth, a thin net margin and relatively low return on equity reinforce those concerns. Pfizer Dividend Yield Analysis
• Negative Sentiment: Cost-cutting highlights operational pressure: Pfizer plans to close a penicillin unit in Italy and eliminate about 330 jobs, underscoring efforts to improve efficiency amid a challenging growth outlook. Pfizer Italy Penicillin Unit Closure

Pfizer Stock Performance

Shares of PFE opened at $28.27 on Friday. Pfizer Inc. has a one year low of $23.62 and a one year high of $29.21. The company has a market cap of $161.14 billion, a PE ratio of 37.20, a P/E/G ratio of 1.87 and a beta of 0.32. The stock has a 50-day moving average of $27.68 and a 200-day moving average of $26.50. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.27 and a quick ratio of 0.96.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.68 by $0.09. The business had revenue of $15.03 billion for the quarter, compared to analyst estimates of $14.40 billion. Pfizer had a return on equity of 19.63% and a net margin of 6.80%. The company’s quarterly revenue was up 2.6% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.78 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, equities research analysts predict that Pfizer Inc. will post 2.98 EPS for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 7th. Investors of record on Friday, November 6th will be given a $0.43 dividend. The ex-dividend date of this dividend is Friday, November 6th. This represents a $1.72 annualized dividend and a yield of 6.1%. Pfizer’s dividend payout ratio (DPR) is presently 226.32%.

Pfizer Profile

Pfizer Inc (NYSE:PFE) is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research and commercial activities focus on areas including oncology, inflammation and immunology, internal medicine, hospital care and vaccines.

The company’s portfolio includes widely used products such as the Prevnar family of pneumococcal vaccines, Ibrance for certain breast cancers, Eliquis for preventing blood clots, Xeljanz for inflammatory conditions, and Vyndaqel for transthyretin amyloidosis.